Skip to content

Reimbursement Information

Reimbursement information on coding, coverage and payment amounts for Ultromics EchoGo® Heart Failure

Our Partnership Goals are to: 



  • Help achieve faster and more precise heart failure diagnoses that will improve patient outcomes 
  • Widen our existing knowledge base and increase our expertise on heart failure
  • Continue to speed up AI innovation and scale up our platforms

 



  • Maintain our close connections within the global scientific community
  • Increase inter-industry and academic-industry collaborations

What We Have Achieved with our Partnerships

Published Research and Validation

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE. 

Reliability in the heart failure sector

With our partners’ continuous support, our technology has proven its reliability through commercial clearances, including three FDA clearances, two CE marks, and two FDA breakthrough designations. 

Access to world-leading science and data

Our technology was built on ten years of outcome data. We were born out of Oxford University from leading minds in science and built in partnership with the U.K.’s National Health Service (NHS).  

We are committed to ongoing partnerships with leading organizations as we seek to achieve continuous improvement of our unparalleled AI technology. 

Building a community of medical and tech experts

We have brought together some of the world’s top experts in both medical science and AI technology to maximize the application of our groundbreaking platform. We’ve built a world-leading Scientific Advisory Board with key industry experts from Northwestern Medicine, Baylor Scott & White, Mayo Clinic, and Harvard Medical Center.

 

What others say about our partnerships:



After Ultromics joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF), which includes the National Heart Lung and Blood Institute (NHLBI): 

Reimbursement Resources

EchoGo® is a revolutionary AI-powered platform designed to assist healthcare professionals in the diagnosis and management of cardiac diseases. The technology utilizes advanced artificial intelligence to detect disease non-invasively using echocardiography, providing diagnostic outputs to support in the timely detection and effective management of diseases.

EchoGo® Heart Failure

EchoGo® Heart Failure is eligible for reimbursement in both outpatient and inpatient settings.

Below you will find the necessary coding information and payment methodologies for ensuring proper reimbursement. 

Hospital Outpatient

In the hospital outpatient setting, the hospital can bill for the technical component by using CPT code 0932T. This is paid through the Ambulatory Payment Classification (APC) system. APC 5743 has a national average of $316.08 which will be wage-adjusted for each hospital locality.

 

 

Hospital InPatient

EchoGo is reimbursed under the DRG payment methodology. CMS continues to pay for new technologies through the regular payment mechanism established by the DRG payment methodology. Whether a technology receives new technology add-on payments or not does not affect coverage of the technology or the ability for hospitals to provide a technology to patients where appropriate.

 

Physician

In any place of service, the professional component for interpretation and report, is billed using code 0932T with modifier -26. The reimbursement rate will be carrier priced.

Questions?

Ultromics is working closely with providers to establish coverage with commercial players.
For specific reimbursement
questions, please contact us directly.